Citius Pharmaceuticals (STU:47N0) Inventories, Work In Process: €6.01 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:47N0 Citius Pharmaceuticals Inc STU:47N0
25 GF Score
Price €3.29
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals Inventories, Work In Process?

Citius Pharmaceuticals STU:47N0 25 Inventories, Work In Process is €6.01 Mil as of Mar. 2026. GuruFocus rates STU:47N0 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Citius Pharmaceuticals's work in process for the quarter that ended in Mar. 2026 was €6.01 Mil.

Citius Pharmaceuticals Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Citius Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Inventories, Work In Process Chart

Citius Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.92 9.98

Citius Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 9.98 5.94 6.01
STU:47N0
25GF Score
Citius Pharmaceuticals Inc STU:47N0
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €6.01 Mil mean?
Citius Pharmaceuticals (STU:47N0) has a Inventories, Work In Process of €6.01 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Citius Pharmaceuticals and its competitors.
Is Citius Pharmaceuticals' Inventories, Work In Process too high?
Citius Pharmaceuticals' current Inventories, Work In Process is €6.01 Mil. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Inventories, Work In Process compare to LEXX and HIND?
Citius Pharmaceuticals' Inventories, Work In Process of €6.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Citius Pharmaceuticals and its competitors. Citius Pharmaceuticals's current Inventories, Work In Process is €6.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (STU:47N0) has a current Inventories, Work In Process of €6.01 Mil. The current Inventories, Work In Process is €6.01 Mil. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Citius Pharmaceuticals (STU:47N0), the current Inventories, Work In Process is €6.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Other Exchanges CTXR:USA
Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score

Get the complete analysis for STU:47N0

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.29
Price